The high incidence of gastric cancer(GC) and its consequent mortality rate severely threaten human health. GC is frequently not diagnosed until a relatively advanced stage. Surgery is the only potentially curative treatment. Thus,early screening and diagnosis are critical for improving prognoses in patients with GC. Gastroscopy with biopsy is an appropriate method capable of aiding the diagnosis of specific early GC tumor types;however,the stress caused by this method together with it being excessively expensive makes it difficult to use it as a routine method for screening for GC on a population basis. The currently used tumor marker assays for detecting GC are simple and rapid,but their use is limited by their low sensitivity and specificity. In recent years,several markers have been identified and tested for their clinical relevance in the management of GC.Here,we review the serum-based tumor markers for GC and their clinical significance,focusing on discoveries from microarray/proteomics research.We also review tissue-based GC tumor markers and their clinical application,focusing on discoveries from immunohistochemical research.This review provides a brief description of various tumor markers for the purposes of diagnosis,prognosis and therapeutics,and we include markers already in clinical practice and various forthcoming biomarkers. The high incidence of gastric cancer (GC) and its consequent mortality rate severely threaten human health. Thus, it is not only diagnosed until a relatively advanced stage. Surgery is the only potentially curative treatment. Thus, early screening and diagnosis are critical for improving prognoses in patients with GC. Gastroscopy with biopsy is an appropriate method capable of aiding the diagnosis of specific early GC tumor types; however, the stress caused by this method together with it being excessively expensive makes it difficult to use it as a routine method for screening for The currently used tumor marker assays for detecting GC are simple and rapid, but their use is limited by their low sensitivity and specificity. In recent years, several markers have been identified and tested for their clinical relevance in the management of GC. Here, we review the serum-based tumor markers for GC and their clinical significance, focusing on discoveries from microarray / prot we also review tissue-based GC tumor markers and their clinical application, focusing on discoveries from immunohistochemical research. This review provides a brief description of various tumor markers for the purposes of diagnosis, prognosis and therapeutics, and we include markers already in clinical practice and various forthcoming biomarkers